

K050479

MAR 24 2005

### 510(k) Summary

The following information is provided following the format of 21 CFR 807.92 for the 4D Integrated Treatment Console.

1. **Submitter:** Varian Medical Systems  
3100 Hansen Way M/S E-110  
Palo Alto, CA 94304-1129  
Contact Name: Vy Tran  
Phone: (650) 424-5731  
Fax: (650) 842-5040  
Email: [vy.tran@varian.com](mailto:vy.tran@varian.com)  
Date summary was prepared: February 23, 2005
  
2. **Name of the Device:**  
Trade/Proprietary Name: 4D Integrated Treatment Console  
Common or Usual Name: Accessory to Medical Linear Accelerator  
Classification Name: Medical Charged Particle Radiation Therapy System  
21 CFR §892.5050  
Class II  
Product Code: 90 IYE
  
3. Predicate Devices to claim substantial equivalence:
  - a. Varian Medical Systems' Varis 1.4g (K001643)
  
4. Device Description: The 4D Integrated Treatment Console provides the user with:
  - a treatment verification function - to assist the operator of a radiation therapy device in providing accurate treatment setups for each patient by monitoring set up parameters and to prevent the radiation therapy device from commencing irradiation while any parameter is out of conformance with the treatment plan.
  - the ability to select patients from a queue provided by the schedule
  - the ability to retrieve plans from the information system for the selected patient
  - the ability to evaluate a selected treatment plan to determine whether redefined dose limits will be exceeded

- the ability to acquire and edit positional data from radiation therapy devices
  - the ability to override treatment parameters based on user rights
  - the ability to send treatment records to an information system
  - the ability to interact with the user controls of the Portalvision, the multi-leaf collimator system and the treatment verification function on a single workstation.
  - Provides access to the linear accelerator and the On-Board Imager.
5. Intended Use Statement: 4D Integrated Treatment Console is designed to assist the operator of a radiation therapy device in providing accurate treatment set-ups for each patient by monitoring set up parameters and preventing the radiation therapy device from commencing irradiation while any parameter is out of conformance with the treatment plan.
6. Summary of the Technological Characteristics: The Substantial Equivalence Comparison Chart provides a comparison of the technological characteristics to those of the predicate devices. This chart is located in Tab 8 of the submission.



MAR 24 2005

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Ms. Vy Tran  
Corporate Director of Regulatory Affairs  
Varian Medical Systems, Inc.  
3100 Hansen Way  
PALO ALTO CA 94304-1038

Re: K050479  
Trade/Device Name: 4D Integrated  
Treatment Console  
Regulation Number: 21 CFR 892.5050  
Regulation Name: Medical charged-particle  
radiation therapy system  
Regulatory Class: II  
Product Code: IYE  
Dated: February 23, 2005  
Received: February 24, 2005

Dear Ms. Tran:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.


This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

21 CFR 876.xxxx	(Gastroenterology/Renal/Urology)	240-276-0115
21 CFR 884.xxxx	(Obstetrics/Gynecology)	240-276-0115
21 CFR 892.xxxx	(Radiology)	240-276-0120
Other		240-276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Nancy C. Brogdon  
Director, Division of Reproductive,  
Abdominal, and Radiological Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

